Innovent Reports First Participant Dosing of Mazdutide (IBI362) in the P-III (GLORY-1) Trial for the Treatment of Overweight or Obesity
Shots:
- The first patient has been dosed in the P-III (GLORY-1) trial evaluating the efficacy & safety of mazdutide (4/6mg) vs PBO in a ratio (1:1:1) in 600 Chinese adults with overweight or obesity
- The 1EPs include the percentage change in body weight from baseline to 32wk. and the proportion of patients with ≥5% body weight loss from baseline @32wk.
- In the P-II study, the therapy showed 11.57% mean body weight loss @24wk., reduction in waist circumference, blood pressure, lipids, blood uric acid, transaminase & liver fat which offers multiple metabolic benefits to patients. The therapy was well tolerated & the overall safety profile was similar to other GLP-1 class drugs
Ref: PRNewswire | Image: Innovent
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
